Ampersand Capital Partners Invests in iuvo BioScience

iuvo BioScience Acquires Promedica International

January 18, 2024

Healthcare Services

iuvo BioScience, a Rochester-based specialty preclinical and clinical services provider backed by Ampersand Capital Partners, has acquired Promedica International, an ophthalmology-focused clinical CRO headquartered in Costa Mesa, California. The deal combines iuvo's laboratory and consulting capabilities with Promedica's ophthalmic clinical trial expertise to create an integrated end-to-end ophthalmology clinical research offering.

Canyon Labs Acquires iuvo BioScience's Lab Services and Scientific Consulting Divisions

January 7, 2025

Healthcare Services

Canyon Labs has acquired the laboratory services and scientific consulting businesses of iuvo BioScience, integrating the lab and consulting personnel into Canyon Labs' operations while iuvo retains its ophthalmic clinical research team. The deal expands Canyon Labs' testing and consulting capabilities (adding a Rochester, NY site) and allows iuvo to sharpen its focus on ophthalmic clinical trial services.

Ampersand Capital Partners Acquires Biologos LLC

March 19, 2024

Biotechnology

Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.

Ampersand Capital Partners Invests in AnaBios Corporation

June 7, 2022

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

Ampersand Capital Partners Invests in BioEcho Life Sciences

March 1, 2022

Biotechnology

Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.